ArteraNova Therapeutics
ArteraNova Therapeutics is addressing the persistent challenge of restenosis following vascular interventions for arterial diseases, a complication that continues to affect millions of patients despite modern drug-eluting technologies. Through NanoSmooth, our proprietary peptide-nanoparticle platform, we selectively target the biological pathway that drives pathological vessel re-narrowing while preserving natural healing. By combining precision delivery with a biologically targeted mechanism, we aim to reduce repeat procedures and deliver safer, more durable outcomes in vascular care.
Contact: mail@arteranova.com; michelle.bendeck@utoronto.ca